The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
Agendia received FDA clearance to market its MammaPrint test, a gene test to help predict breast cancer relapse
in five or 10 years.
Althea
Technologies is developing a molecular diagnostic
capable of clearly differentiating various types of childhood cancers known as Small Round Blue Cell Tumors. These include: neuroblastoma,
rhadbomyosarcoma, non-Hodgkin's lymphoma, and Ewing's family of tumors.
Applied
Biosystems introduced a reagent kit designed to
improve the workflow for DNA sequencing. The BigDye XTerminator Purification Kit is
designed for the purification step in the Sanger Sequencing workflow.
Bruker
Daltonics, a subsidiary of Bruker BioSciences, and Isis Pharmaceuticals formed a strategic
alliance for manufacturing and distribution of Isis' Ibis T5000 biosensor system.
The can simultaneously identify thousands of types of infectious
organisms in a sample, without needing to know beforehand what might be present
in the sample using Bruker Daltonics' micrOTOF ESI-TOF mass spectrometer.
Cepheid acquired PCR diagnostics company Sangtec Molecular Diagnostics from Altana Pharma for around $27
million in cash. Sangtecs’ line of
products includes assays for cytomegalovirus, Epstein-Barr virus, herpes
simplex virus 1 and 2, hepatitis B virus, Varicella zoster virus, BK virus and
Aspergillus.
![[Page Banner Image]](images/hmole.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
